arrow
Back
R

Ransi Somaratne

IQVIA

24H-index
96Paper Count
4.7KCitation Count
Published Papers 26
Publication Date
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
err2022-04-01
err2
errOAAI
errHonda, Satoshi; Puri, Rishi; Anderson, Todd; Kastelein, John J. P.; Brennan, Danielle M.; Kassahun, Helina; Somaratne, Ransi; Wasserman, Scott M.; Nissen, Steve E.; Nicholls, Stephen J.
errShare
errSave
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
err2020-09-01
err5
errOAAI
errNelson, Adam J.; Puri, Rishi; Brennan, Danielle M.; Anderson, Todd J.; Cho, Leslie; Ballantyne, Christie M.; Kastelein, John Jp; Koenig, Wolfgang; Kassahun, Helina; Somaratne, Ransi M.; Wasserman, Scott M.; Nissen, Steven E.; Nicholls, Stephen J.
errShare
errSave
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction
err2020-03-01
err11
PREAI
errBrown, Todd M.; Bittner, Vera; Colantonio, Lisandro D.; Deng, Luqin; Farkouh, Michael E.; Limdi, Nita; Monda, Keri L.; Rosenson, Robert S.; Serban, Maria-Corina; Somaratne, Ransi M.; Zhao, Hong; Woodward, Mark; Muntner, Paul
errShare
errSave
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
err2019-04-05
err55
errOAAI
errRosenson, Robert S.; Daviglus, Martha L.; Handelsman, Yehuda; Pozzilli, Paolo; Bays, Harold; Monsalvo, Maria Laura; Elliott-Davey, Mary; Somaratne, Ransi; Reaven, Peter
errShare
errSave
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
err2018-09-01
err25
errOAAI
errGaudet, Daniel; Langslet, Gisle; Gidding, Samuel S.; Luirink, Ilse K.; Ruzza, Andrea; Kurtz, Christopher; Lu, Chen; Somaratne, Ransi; Raal, Frederick J.; Wiegman, Albert
errShare
errSave
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies
err2018-08-02
err21
PREAI
errCho, Leslie; Dent, Ricardo; Stroes, Erik S. G.; Stein, Evan A.; Sullivan, David; Ruzza, Andrea; Flower, Andrea; Somaratne, Ransi; Rosenson, Robert S.
errShare
errSave
Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia
err2018-07-01
err2
PREAI
errRosenson, Robert S.; Daviglus, Martha L.; Reaven, Peter; Pozzilli, Paolo; Bays, Harold; Monsalvo, Maria Laura; Elliott, Mary; Somaratne, Ransi; Handelsman, Yehuda
errShare
errSave
NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage-Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH)
err2018-07-01
err1
PREAI
errDepaoli, Alex; Rossi, Stephen J.; Ling, Lei; Harrison, Stephen A.; Abdelmalek, Manal F.; Jaros, Mark R.; Somaratne, Ransi
errShare
errSave
NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial
err2018-04-01
err2
PREAI
errHirschfield, G.; Chazouilleres, O.; Drenth, J. Ph; Thorburn, D.; Harrison, S.; Landis, C.; Mayo, M. J.; Muir, A.; Trotter, J. F.; Karsdal, M.; Jaros, M.; Ling, L.; Kim, K. H.; Rossi, S.; Somaratne, R. M.; Depaoli, A.; Beuers, U.
errShare
errSave
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
err2018-03-20
err42
PREAI
errMefford, Matthew T.; Rosenson, Robert S.; Cushman, Mary; Farkouh, Michael E.; McClure, Leslie A.; Wadley, Virginia G.; Irvin, Marguerite R.; Bittner, Vera; Safford, Monika M.; Somaratne, Ransi; Monda, Keri L.; Muntner, Paul; Levitan, Emily B.
errShare
errSave
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
err2017-12-01
err84
errOAAI
errGiugliano, Robert P.; Keech, Anthony; Murphy, Sabina A.; Huber, Kurt; Tokgozoglu, S. Lale; Lewis, Basil S.; Ferreira, Jorge; Pineda, Armando Lira; Somaratne, Ransi; Sever, Peter S.; Pedersen, Terje R.; Sabatine, Marc S.
errShare
errSave
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
err2017-10-01
err118
errOAAI
errFonarow, Gregg C.; Keech, Anthony C.; Pedersen, Terje R.; Giugliano, Robert P.; Sever, Peter S.; Lindgren, Peter; van Hout, Ben; Villa, Guillermo; Qian, Yi; Somaratne, Ransi; Sabatine, Marc S.
errShare
errSave
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
errLANCET
IF88.5
err2017-10-01
err484
PREAI
errGiugliano, Robert P.; Pedersen, Terje R.; Park, Jeong-Gun; De Ferrari, Gaetano M.; Gaciong, Zbigniew A.; Ceska, Richard; Toth, Kalman; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Schiele, Francois; Mach, Francois; Ott, Brian R.; Kanevsky, Estelle; Pineda, Armando Lira; Somaratne, Ransi; Wasserman, Scott M.; Keech, Anthony C.; Sever, Peter S.; Sabatine, Marc S.
errShare
errSave
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
err2017-05-09
err67
errOAAI
errToth, Peter P.; Descamps, Olivier; Genest, Jacques; Sattar, Naveed; Preiss, David; Dent, Ricardo; Djedjos, Constantine; Wu, Yuna; Geller, Michelle; Uhart, Magdalena; Somaratne, Ransi; Wasserman, Scott M.
errShare
errSave
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
err2016-12-13
err853
errOAAI
errNicholls, Stephen J.; Puri, Rishi; Anderson, Todd; Ballantyne, Christie M.; Cho, Leslie; Kastelein, John J. P.; Koenig, Wolfgang; Somaratne, Ransi; Kassahun, Helina; Yang, Jingyuan; Wasserman, Scott M.; Scott, Robert; Ungi, Imre; Podolec, Jakub; Ophuis, Antonius Oude; Cornel, Jan H.; Borgman, Marilyn; Brennan, Danielle M.; Nissen, Steven E.
errShare
errSave
EFFICACY AND SAFETY OF EVOLOCUMAB IN PATIENTS ON HIGH- VS MODERATE-INTENSITY BACKGROUND STATIN THERAPY
err2016-09-01
err0
PREAI
errSoran, H.; Lira, A.; Dent, R.; Bridges, I.; Somaratne, R.; Koren, M.
errShare
errSave
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency (vol 18, pg 482, 2016)
err2016-06-20
err1
errOAAI
errAnker, Stefan D.; Schroeder, Stefan; Atar, Dan; Bax, Jeroen J.; Ceconi, Claudio; Cowie, Martin R.; Crisp, Adam; Dominjon, Fabienne; Ford, Ian; Ghofrani, Hossein-Ardeschir; Gropper, Savion; Hindricks, Gerhard; Hlatky, Mark A.; Holcomb, Richard; Honarpour, Narimon; Jukema, J. Wouter; Kim, Albert M.; Kunz, Michael; Lefkowitz, Martin; Floch, Chantal Le; Landmesser, Ulf; McDonagh, Theresa A.; McMurray, John J.; Merkely, Bela; Packer, Milton; Prasad, Krishna; Revkin, James; Rosano, Giuseppe M. C.; Somaratne, Ransi; Stough, Wendy Gattis; Voors, Adriaan A.; Ruschitzka, Frank
errShare
errSave
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
err2016-06-01
err47
PREAI
errPuri, Rishi; Nissen, Steven E.; Somaratne, Ransi; Cho, Leslie; Kastelein, John J. P.; Ballantyne, Christie M.; Koenig, Wolfgang; Anderson, Todd J.; Yang, Jingyuan; Kassahun, Helina; Wasserman, Scott M.; Scott, Robert; Borgman, Marilyn; Nicholls, Stephen J.
errShare
errSave
COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
err2016-05-01
err0
errOAAI
errGandra, S. R.; Villa, G.; Fonarow, G.; Lothgren, M.; Lindgren, P.; Somaratne, R.; van Hout, B.
errShare
errSave